All In Biotech

Drug Trial Radar · NCT05289492

Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma

Study of EOS884448 Alone, and in Combination with Iberdomide with or Without Dexamethasone, in Participants with Relapsed or Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Oct 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

16

Actual

Start

May 1, 2022

Primary completion

Nov 29, 2023

Study completion Nov 29, 2023

Sponsor

Lead sponsor
iTeos TherapeuticsIndustry
Sponsor type
Industry
Collaborators
Bristol-Myers Squibb; GlaxoSmithKline; iTeos Belgium SA
First posted
Mar 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label, phase I/II clinical study, to assess the safety, tolerability, antitumor activity, pharmacokinetics and pharmacodynamics of EOS884448 (also known as EOS-448 or GSK4428859A), alone or in combination with iberdomide with and without dexamethasone in participants with relapsed/refractory multiple myeloma (RRMM).

Conditions

  • Multiple Myeloma

Interventions

  • EOS884448Drug

    EOS884448 will be administered in arm A,B and C

  • IberdomideDrug

    Iberdomide will be administered in arm B and C

  • DexamethasoneDrug

    Dexamethasone will be administered in arm C

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with any adverse events (AEs) and serious adverse events (SAEs)Time frame: From first study treatment administration up to 120 days after the last dose
  2. Number of participants with dose limiting toxicity (DLT)Time frame: From first study treatment administration up to 120 days after the last dose
  3. Recommended Phase 2 dose (RP2D) of EOS884448 alone or in combinations with iberdomide with or without dexamethasone in participants with relapse/refractory multiple myelomaTime frame: up to 2 years
  4. Number of participants with overall response (partial or better) as determined by IMWG criteriaTime frame: up to 2 years

Locations

13 sites in 4 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson

    Gilbert, Arizona

  • Eastern Connecticut Hematology & Oncology

    Norwich, Connecticut

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Fred Hutchinson Cancer Center

    Seattle, Washington

  • ZNA Cadix

    Antwerp, Belgium

  • Institut Jules Bordet

    Brussels, Belgium

  • Universitaire Ziekenhuizen KU Leuven

    Leuven, Belgium

  • CHU Amiens

    Amiens, France

  • Centre Hospitalier Universitaire de Nantes

    Nantes, France

  • APHP Hôpital Saint-Antoine

    Paris, France

  • CHU de Poitiers

    Poitiers, France

  • CHU Toulouse

    Toulouse, France

  • Hospital Fundacion Jimenez Diaz

    Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.